



Figure 1: Trial profile of NeoSep1 Part 1



¹ 1 withdrew; ² PK processing was unavailable at the time for 2 neonates

Figure 2: Observed antibiotic concentration versus time

A: Observed fosfomycin concentrations vs time on Day 1 for neonates in Cohort 1 and 3 (n=39)



B: Observed flomoxef concentrations vs time on Day 1 for neonates in Cohort 2 and 3 (n=40)





Figure 3: Probability of target attainment (PTA) for different postnatal age (PNA) groups

A: PTA for different PNA groups achieving target AUC_{0-24}/MIC ratio of 83, in simulated neonates after administration of fosfomycin, as per dosing schedule. Fosfomycin was given at 100 mg/kg intravenously (IV) twice daily for preterm infants if postnatal age (PNA) was ≤ 7 days or current weight < 1.5 kg, and at 150 mg/kg IV twice daily if PNA ≥ 8 days and ≥ 1.5 kg. Term neonates received fosfomycin 150 mg/kg IV twice daily. The dash grey line represents a PTA of 90%



B: PTA for different PNA achieving target $\%fT > MIC$ of 40 in simulated neonates after administration of flomoxef, as per dosing schedule. Flomoxef was given at 40 mg/kg IV three times daily if PNA ≤ 7 days, and 50 mg/kg IV three times daily if PNA ≥ 8 days, regardless of gestational age. The dash grey lines represent a PTA of 90%.

